Asset Details
Do you wish to reserve the book?
Antipsychotic Abuse and Dependence: A 10-year Review of Reports to the European Pharmacovigilance System
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antipsychotic Abuse and Dependence: A 10-year Review of Reports to the European Pharmacovigilance System
Do you wish to request the book?
Antipsychotic Abuse and Dependence: A 10-year Review of Reports to the European Pharmacovigilance System
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antipsychotic Abuse and Dependence: A 10-year Review of Reports to the European Pharmacovigilance System
2024
Overview
Aim/Objective: To assess Individual Case Safety Reports (ICSRs) associated with antipsychotic abuse and dependence reported to the European Pharmacovigilance System over the last 10 years. Methods: We conducted a retrospective analysis of ICSRs containing at least one medicinal product classified under the Anatomical Therapeutic Chemical (ATC) group NO5A (antipsychotics), reported as suspect or interacting to the EudraVigilance database, from January 1, 2014, to December 31, 2023. ICSRs with at least one MedDRA Preferred Term (PT) under the Standardised MedDRA Query (SMQ) narrow terms \"Drug abuse and dependence\" were included. The number of ICSRs per ATC 4th and 5th level was measured, along with patient demographic data, category of adverse drug reaction (MedDRA PT), seriousness, and the type of pharmacological substance reported concomitantly. Descriptive methods were used for statistical analysis. Results: A total of 8613 ICSRs were identified, with 52.4% (n = 4512) of these concerning women and 71.0% (n = 6113) involving individuals aged between 18 and 64 years old. Among the ICSRs, the majority (57.1%; n = 4914), contained at least one medicinal product classified under the ATC group N05AH (diazepines, oxazepines, thiazepines, and oxepines), with quetiapine being the most reported medicinal product, representing 36.7% (n = 3164) of the total reports. Regarding seriousness, 95.3% (n = 8205) of the ICSRs were classified as serious, with 39.7% (n = 3420) leading to hospitalization and 13.9% (n = 1201) resulting in the death of the individual. One-fifth of the reports (n = 1735) were related to cases of suicide attempt. Somnolence was the most frequently reported adverse drug reaction, occurring in 11.4% (n = 984) of cases. The most frequently reported therapeutic classes concomitantly were antidepressants, anxiolytics, and antiepileptics, noting that approximately 8% (n = 662) of the ICSRs referred to the concurrent use of ethanol, cocaine, or cannabis. Conclusion: Our findings reinforce the urgent need to address antipsychotic abuse and dependence, given their profound societal implications. Furthermore, it is important to note that the extent of this issue may exceed our current understanding, due to potential underreporting and the influence of existing pharmacovigilance regulations.
Publisher
Springer Nature B.V
Subject
